Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This phase II study assesses the efficacy of the combination of olaparib and durvalumab in
the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib may
stop growth of tumors cells by inhibiting some of the enzymes (ADP ribose polymerase [PARP])
needed for cell growth. Durvalumab, a monoclonal antibody, inhibits the growth and spread of
tumors by stimulating the patient's antitumor immune response. Giving olaparib and durvalumab
together may provide an effective method to treat patients with metastatic triple negative
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
AstraZeneca Oregon Health and Science University
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Olaparib Poly(ADP-ribose) Polymerase Inhibitors